Dishman Carbogen Amcis Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Dishman Carbogen Amcis' wholly owned subsidiary, CARBOGEN AMCIS AG, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced a strategic co-investment of more than CHF 25 million with a long-standing Japanese customer to expand manufacturing capabilities at its sites in Aarau and Neuland, Switzerland.

The investment will support the production of a drug linker for a commercial antibody-drug conjugate (ADC), enabling CARBOGEN AMCIS to meet rising global demand. As part of the agreement, both facilities will see significant equipment and infrastructure enhancements, including:

? Aarau site: installation of 850-litre reactors and 0.4 m? agitated filter dryers with supporting equipment. Completion is expected by Q1 2027.

? Neuland site: installation of 850-litre reactors and 0.4 m? agitated filter dryers with auxiliary systems. Completion is anticipated by Q3 2027.

This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021 to develop a site extension at the Bubendorf site in Switzerland, reinforcing the strength of the relationship and their shared commitment to long-term growth.

Powered by Capital Market - Live News

Consolidated net sales rose 9.41% year-on-year to Rs 716.34 crore in Q4 March 2025. Pre-tax profit before exxceptional items stood at Rs 39.45 crore in Q4 FY25 as against pre-tax loss before exceptional items of Rs 46.11 crore in Q4 FY24.

For the full year, the company reported net profit of Rs 3.24 crore in the year ended March 2025 as against net loss of Rs 153.45 crore in the year ended March 2024. Net sales rose 3.66% YoY to Rs 2711.50 crore in the year ended March 2025. Pre-tax profit before exceptional items stood at Rs 37.42 crore in FY25 as against pre-tax loss before exceptional items of Rs 116.12 crore in FY24.

During the quarter and year ended 31 March 2025, certain subsidiaries discarded some of their inventories, which was not expected to be usable for projects that the company estimated to undertake in near to mid-term. The loss on account of these impairment were Rs 0.77 crore and Rs 7.13 crore respectively for the quarter and year. Further, during the quarter ended 31 March 2025, one of the subsidiaries Carbogen Amcis AG, had impaired expenditure incurred for capex project. The loss on account of this impairment was Rs 10.98 crore for the quarter and the year.

The company's consolidated net cash from operating activities stood at Rs 375.23 crore in FY25, lower than Rs 379.43 crore in FY24.

Dishman Carbogen Amcis is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services. It provides a range of development and manufacturing solutions at locations in Europe, China and in India.

Powered by Capital Market - Live News

Net profit of Dishman Carbogen Amcis reported to Rs 43.09 crore in the quarter ended March 2025 as against net loss of Rs 69.92 crore during the previous quarter ended March 2024. Sales rose 9.41% to Rs 716.34 crore in the quarter ended March 2025 as against Rs 654.71 crore during the previous quarter ended March 2024.

For the full year,net profit reported to Rs 3.24 crore in the year ended March 2025 as against net loss of Rs 153.45 crore during the previous year ended March 2024. Sales rose 3.66% to Rs 2711.50 crore in the year ended March 2025 as against Rs 2615.77 crore during the previous year ended March 2024.

Powered by Capital Market - Live News

Net Loss of Dishman Carbogen Amcis reported to Rs 7.37 crore in the quarter ended March 2025 as against net loss of Rs 31.12 crore during the previous quarter ended March 2024. Sales declined 4.64% to Rs 106.10 crore in the quarter ended March 2025 as against Rs 111.26 crore during the previous quarter ended March 2024.

For the full year,net loss reported to Rs 9.87 crore in the year ended March 2025 as against net loss of Rs 76.41 crore during the previous year ended March 2024. Sales rose 22.14% to Rs 399.84 crore in the year ended March 2025 as against Rs 327.35 crore during the previous year ended March 2024.

Powered by Capital Market - Live News